<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418067</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0136</org_study_id>
    <nct_id>NCT00418067</nct_id>
  </id_info>
  <brief_title>Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions</brief_title>
  <acronym>ZEST</acronym>
  <official_title>Comparison of the Efficacy and the Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety and long-term effectiveness of coronary&#xD;
      stenting with the ABT 578-eluting balloon expandable stent (Medtronic, Minneapolis, MN) vs.&#xD;
      the sirolimus-eluting balloon expandable stent (Cordis Johnson &amp; Johnson, Warren, New Jersey)&#xD;
      and the paclitaxel-eluting stent (Taxus liberte, Boston Scientific) for the treatment of&#xD;
      coronary stenosis in routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have documented that a slow-release polymeric sirolimus-eluting stent&#xD;
      (Cypher, Cordis) and paclitaxel-eluting stent (Taxus, Boston Scientific) reduce neointimal&#xD;
      formation and result in decrease of angiographic restenosis and target lesion&#xD;
      revascularization at 1-3 years in the multicenter randomized clinical trials RAVEL, SIRIUS,&#xD;
      and TAXUS I-VI.From these studies, the two leading drug-eluting stents (DESs) of the Cypher&#xD;
      and Taxus have been widely and rapidly accepted as a standard treatment of coronary lesions.&#xD;
&#xD;
      Recently, randomized studies were conducted to reveal different outcomes of the different two&#xD;
      DESs. These studies showed that the sirolimus-eluting stent was better than the&#xD;
      paclitaxel-eluting stent in terms of lower angiographic restenosis rate or the two DESs were&#xD;
      similar in angiographic outcomes. A recent meta-analysis supported results of the former&#xD;
      randomized studies. Patients receiving sirolimus-eluting stent had a significantly lower risk&#xD;
      of restenosis and target vessel revascularization compared with those receiving&#xD;
      paclitaxel-eluting stent.&#xD;
&#xD;
      With a recent approval of new DES, ABT-578-eluting stent (Endeavor, Medtronic, Minneapolis,&#xD;
      MN), other comparison studies have been conducted to compare Endeavor ABT-578-eluting stent&#xD;
      with the sirolimus-eluting stent and paclitaxel-eluting stent. ABT-578 and sirolimus share&#xD;
      some common structural and biological properties. The ENDEAVOR clinical trials are currently&#xD;
      in progress to evaluate a phosphoryl choline (PC)-coated ABT-578-eluting stent for the&#xD;
      prevention of restenosis. The Endeavor ABT-578-eluting stent utilizes a cobalt alloy&#xD;
      balloon-expandable stent (Driver; Medtronic) with a geometry similar to the stainless steel&#xD;
      stent used in this preliminary study (S7; Medtronic). The Endeavor ABT-578-eluting stent also&#xD;
      employees a PC strut surface coating as the drug delivery reservoir with a dose of 10 ug/mm&#xD;
      of ABT-578. The Endeavor ABT-578-eluting stent, however, differs from the stent used in this&#xD;
      experimental study by the addition of a drug-free PC coating to serve as a diffusion barrier&#xD;
      to retard drug release from the polymer reservoir. Angiographic analysis at 4 months in the&#xD;
      100-patient focal de novo lesion ENDEAVOR I feasibility study demonstrated a mean in-stent&#xD;
      percent diameter stenosis of approximately 14% and a late lumen loss of 0.3 mm with a low&#xD;
      frequency of target lesion revascularization (1%). The clinical outcomes from the ENDEAVOR II&#xD;
      (1,500 patients randomized to ABT-578 or bare metal stent) and the ENDEAVOR III (436 patients&#xD;
      randomized 3:1 to ABT-578 or Cypher) trials as well as other ongoing studies showed efficacy&#xD;
      of the PC-coated ABT-578-eluting stent. In ENDEAVOR III study, the Endeavor stent had larger&#xD;
      late loss and higher binary restenosis in both the analysis segment and stented segment. In&#xD;
      contrast, the TLR rates are not statistically different between the Endeavor (6.0%) and the&#xD;
      Cypher (5.3%, p=1.0) stents. This result of this study raised several questions to warrant&#xD;
      further randomized studies 1) is the angiographic superiority of Cypher stent applied to the&#xD;
      more complex lesions, 2) why is the TLR rate similar in spite of significantly different&#xD;
      angiographic outcomes, 3) which is better in the Endeavor and the Taxus stents, etc. The&#xD;
      ENDEAVOR IV study is being conducted to compare the safety and efficacy of the Endeavor stent&#xD;
      versus the Taxus stent. However, the inclusion of ENDEAVOR IV study was also limited that&#xD;
      this study did not include all complex lesions. Because of the limitations of current&#xD;
      ENDEAVOR series, a further large randomized study for the concurrent comparison of the three&#xD;
      DESs in the treatment of real-world practice would be needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite of death (all cause-mortality), myocardial infarction, and ischemia-driven target vessel revascularization</measure>
    <time_frame>at 12 months after the index procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Death</measure>
    <time_frame>In-hospital, 30 days, 6 months, 1 year, and thereafter annually upto 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>In-hospital, 30 days, 6 months, 1 year, and thereafter annually upto 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>In-hospital, 30 days, 6 months, 1 year, and thereafter annually upto 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (all and ischemia-driven)</measure>
    <time_frame>In-hospital, 30 days, 6 months, 1 year, and thereafter annually upto 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (all and ischemia-driven)</measure>
    <time_frame>In-hospital, 30 days, 6 months, 1 year, and thereafter annually upto 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis by definition of Academic Research Consortium (ARC)</measure>
    <time_frame>In-hospital, 30 days, 6 months, 1 year, and thereafter annually upto 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late luminal loss in both in-stent and in-segment</measure>
    <time_frame>at 8 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis in both in-stent and in-segment</measure>
    <time_frame>At 8 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success defined as achievement of a final diameter stenosis of &lt;30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or urgent revascularization during the hospital stay.</measure>
    <time_frame>In-hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2645</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cypher</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxus Liberte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endeavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zotarolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endeavor</intervention_name>
    <description>Zotarolimus-eluting stent</description>
    <arm_group_label>Endeavor</arm_group_label>
    <other_name>Zotarolimus-eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cypher</intervention_name>
    <description>Sirolimus-eluting stent</description>
    <arm_group_label>Cypher</arm_group_label>
    <other_name>Sirolimus-eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus Liberte</intervention_name>
    <description>Paclitaxel-eluting stent</description>
    <arm_group_label>Taxus Liberte</arm_group_label>
    <other_name>Paclitaxel-eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must be at least 18 years of age.&#xD;
&#xD;
          -  Significant coronary artery stenosis (&gt;50% by visual estimate)&#xD;
&#xD;
          -  Patients with stable (CCS class 1 to 4) or acute coronary syndromes (unstable angina&#xD;
             pectoris class IB, IC, IIB, IIC, IIIB, IIIC or NSTEMI) or patients with atypical chest&#xD;
             pain or without symptoms but having documented myocardial ischemia, amenable to&#xD;
             stent-assisted percutaneous coronary intervention&#xD;
&#xD;
          -  The patient or guardian agrees to the study protocol and the schedule of clinical and&#xD;
             angiographic follow-up, and provides informed, written consent, as approved by the&#xD;
             appropriate Institutional Review Board/Ethical Committee of the respective clinical&#xD;
             site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has a known hypersensitivity or contraindication to any of the following&#xD;
             medications:&#xD;
&#xD;
             â€¢ Heparin, Aspirin, Both Clopidogrel and Ticlopidine, Sirolimus, paclitaxel, ABT 578,&#xD;
             Stainless steel and/or Contrast media (patients with documented sensitivity to&#xD;
             contrast which can be effectively pre-medicated with steroids and diphenhydramine&#xD;
             [e.g. rash] may be enrolled. Patients with true anaphylaxis to prior contrast media,&#xD;
             however, should not be enrolled).&#xD;
&#xD;
          -  Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study.&#xD;
&#xD;
          -  Current known current platelet count &lt;100,000 cells/mm3 or Hgb &lt;10 g/dL.&#xD;
&#xD;
          -  An elective surgical procedure is planned that would necessitate interruption of&#xD;
             antiplatelet drugs during the first 12 months post enrollment.&#xD;
&#xD;
          -  Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
          -  Patients who are actively participating in another drug or device investigational&#xD;
             study, which have not completed the primary endpoint follow-up period.&#xD;
&#xD;
          -  Patients who have target lesion of in-stent restenosis at the stented segment of&#xD;
             drug-eluting stent (in-stent restenosis of bare metal stent can be included).&#xD;
&#xD;
          -  Patients with EF&lt;30%.&#xD;
&#xD;
          -  Patients with cardiogenic shock&#xD;
&#xD;
          -  Acute STEMI patients within symptom onset &lt; 12 hours needing primary angioplasty&#xD;
&#xD;
          -  Creatinine level &gt; 3.0mg/dL or dependence on dialysis.&#xD;
&#xD;
          -  Severe hepatic dysfunction (AST and ALT &gt; 3 times upper normal reference values).&#xD;
&#xD;
          -  Patients with left main stem stenosis (&gt;50% by visual estimate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>GangNeung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHIC Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan Natioanal University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>PyeongChon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Mary's Catholic Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>August 20, 2012</last_update_submitted>
  <last_update_submitted_qc>August 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>Comparison of the Efficacy of Zotarolimus(ABT 578)-Eluting Stent versus Sirolimus-Eluting Stent versus Paclitaxel-Eluting Stent for Coronary Lesions: The Prospective, Randomized, and Multi-center Trial</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

